Nome Químico: (4S)-4-Ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl 1,4′-bipiperidine-1′-carboxylate hydrochloride trihydrate (as per EP); (S)-4-Ethyl-4-hydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quin oline-3,14(4H,12H)-dione-9-yl (1,4′-bipiperidine)-1′-carboxylate hydrochloride trihydrate (as per USP)
Sinônimo: 11-Desethyl Irinotecan (as per EP)
Sorrisos: O[C@@](C(OC1)=O)(CC)C2=C1C(N3C(C4=NC5=CC=C(OC(N6CCC(N7CCCCC7)CC6)=O)C=C5C=C4C3)=C2)=O.[3H2O].Cl
Inchi: InChI=1/C10H25NO11P2/c1-6(21-5-10(11,3-12)4-13)9(15)24(19,20)22-7(2)8(14)23(16,17)18/h6-9,12-15H,3-5,11H2,1-2H3,(H,19,20)(H2,16,17,18)
RP-HPLC method development and validation for the simultaneous estimation of Irinotecan hydrochloride and Capecitabine in Active Pharmaceutical Ingredients (APIs)
By Vijaya Jyothi, M.; Bhargav, E.; Keerthana, B.; Varalakshmi, Devi K.
From International Journal of Research in Pharmaceutical Sciences (Madurai, India) (2018), 9(1), 63-67
Method development, validation and forced degradation studies of Irinotecan in bulk and pharmaceutical dosage form
By Swathi, Koduru; Farooqui, Tahmeena; Muntaha, Sidra Tul; Ayesha, Syeda Amtul; Shama, Syeda; Siddiqui, Sarah Imam
From World Journal of Pharmacy and Pharmaceutical Sciences (2018), 7(8), 996-1009